Managers / Q1 2026
Foresite Capital Management VI LLC
CIK 0002013341 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management Vi LLC reported $460M in U.S.-listed holdings across 17 positions for Q1 2026.
The portfolio is heavily concentrated: CGON alone accounts for 32.7% of reported value.
Compared with Q4 2025, the fund opened 8 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 86.7% · $399M
- ADR · 11.8% · $54M
- Other · 1.5% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NERVMinerva Neurosciences, Inc. | NEW | +1.99M | 1.99M | +$12M | $12M |
| TCE2Celldex Therapeutics, Inc. | NEW | +315.9K | 315.9K | +$10M | $10M |
| ATAIAtaiBeckley Inc. | NEW | +2.75M | 2.75M | +$10M | $10M |
| CRNXCrinetics Pharmaceuticals, Inc. | NEW | +212.0K | 212.0K | +$8M | $8M |
| OKUROnKure Therapeutics, Inc. | NEW | +1.45M | 1.45M | +$6M | $6M |
| JBIOJade Biosciences, Inc. | NEW | +320.0K | 320.0K | +$4M | $4M |
| GH Research PLC | NEW | +315.5K | 315.5K | +$4M | $4M |
| Zura Bio Ltd | NEW | +450.0K | 450.0K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CGONCG Oncology, Inc.history → | COM | 32.67% | $150M | 2.22M |
| 2 | ALMSALUMIS INC.history → | COM | 20.33% | $94M | 4.25M |
| 3 | 260Centessa Pharmaceuticals plchistory → | SPONSORED ADS | 11.77% | $54M | 1.36M |
| 4 | CRVSCorvus Pharmaceuticals, Inc.history → | COM | 5.82% | $27M | 1.83M |
| 5 | DNLIDenali Therapeutics Inc.history → | COM | 5.05% | $23M | 1.21M |
| 6 | AGIOAGIOS PHARMACEUTICALS, INC.history → | COM | 3.86% | $18M | 525.0K |
| 7 | VSTMVerastem, Inc.history → | COM | 3.62% | $17M | 3.15M |
| 8 | KYMRKymera Therapeutics, Inc.history → | COM | 2.65% | $12M | 146.3K |
| 9 | NERVMinerva Neurosciences, Inc.history → | COM | 2.60% | $12M | 1.99M |
| 10 | TCE2Celldex Therapeutics, Inc.history → | COM | 2.18% | $10M | 315.9K |
| 11 | ATAIAtaiBeckley Inc.history → | COM | 2.12% | $10M | 2.75M |
| 12 | HNGEHinge Health, Inc.history → | CL A | 1.85% | $8M | 220.4K |
| 13 | CRNXCrinetics Pharmaceuticals, Inc.history → | COM | 1.67% | $8M | 212.0K |
| 14 | OKUROnKure Therapeutics, Inc.history → | COM CL A | 1.30% | $6M | 1.45M |
| 15 | JBIOJade Biosciences, Inc. | COM | 0.98% | $4M | 320.0K |
| 16 | GH Research PLC | ORD | 0.96% | $4M | 315.5K |
| 17 | Zura Bio Ltd | CL A | 0.58% | $3M | 450.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $460M | 17 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $331M | 12 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $259M | 12 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $178M | 20 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $183M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $224M | 14 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.